Listen to this article

Genomic Prediction, a genetic testing company based in North Brunswick, promoted Kelly Ketterson to CEO, effective Oct. 21. 

Ketterson has been the company’s chief operating officer since January, according to an Oct. 21 announcement. 

“Kelly’s decades of experience successfully leading at other top companies in the industry, and the enormous progress she’s made here in her last ten months as COO make this promotion a natural progression,” company co-founder and Chief Science Officer Nathan Treff said in a statement. 

Before joining Genomic Prediction, Ketterson served in leadership roles at CooperSurgical, Reprogenetics, Tyho-Galileo Research Laboratories and Althea Science. 

Ketterson said her work will focus on expanding the company’s “partnerships and research in the ever-changing and fast-paced field of genetic testing.” 

“As an advocate for patient care I want to ensure that every potential reproductive patient has access to make the best informed decisions during their IVF treatment,” she added. 

Genomic Prediction was founded in 2017, according to its website, to provide genetic testing services to patients dealing with infertility.

See also

• Leapfrog Group, Money name 10 NJ hospitals as best for maternity care
• NJ’s first lady continues push on maternal, infant health initiatives